Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study (ACR Convergence 2024) - Sep 25, 2024 - Abstract #0658; Pres time: Nov 16, 2024; 10:30 AM - 12:30 PM; Location: Hall C; In Person; P1/2 | "Results from this subgroup analysis suggest that treatment with zetomipzomib 60 mg once weekly is effective across multiple organ systems in patients with highly active SLE as well as in those with nephrotic range proteinuria (UPCR ≥3)."
Biomarker • Clinical • P1/2 data • Inflammatory Arthritis • Musculoskeletal Diseases • Nephrology • Renal Disease • CD163
|
|
Richard Furie1; Amit Saxena2; Samir Parikh3; Richard Leff4; Lucas Bohnett5; Kathryn Ray6; Brian Tuch4; Janet Anderl4; Jennifer Whang4; Kiruthi Palaniswamy7
|